Clinical Trials Browser

Phase 2/3 × apatinib × 90 days × Clear all

NCT04208347 2026-01-23

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

Phase 2/3 Active not recruiting

Adenocarcinoma

NCT07309419 2025-12-30

Cocktail-001

Phase 2/3 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular